Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. TNGX | 0.00 |
Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ:
TNGX) from Overweight to Neutral and raises the price target from $16 to $24.
